Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Probucol in the Same Patient Group With Non-drug User Group for the Prevention of Cardiovascular Events
Brief Summary: Through this study, the investigators are to prove that Cilostazol effectively prevent cardiovascular events in ischemic stroke patients with high risk of cerebral hemorrhage, along with no significant increase in the risk of occurrence of hemorrhagic side effects.

The primary hypothesis of this study is; Cilostazol alone or with probucol will reduce the risk of cerebral hemorrhage without increase of cardiovascular events compared to aspirin in the ischemic stroke patients with symptomatic or asymptomatic old cerebral hemorrhage.

This study will prove the superiority of cilostazol on the prevention of cerebral hemorrhagic events without increasing the cardiovascular events against aspirin and the superiority of probucol on the prevention of overall cardiovascular events.


Options:
A: Arm Label: Direct Oral Anticoagulant (DOAC); Type: EXPERIMENTAL; Interventions: Drug: Apixaban 5 MG | Arm Label: Left Atrial Appendage Closure (LAAC); Type: EXPERIMENTAL; Interventions: Device: left atrial appendage closure | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Apixaban 5 MG; Assigned to Arm(s): Direct Oral Anticoagulant (DOAC) | Intervention Type: DEVICE; Name: left atrial appendage closure; Assigned to Arm(s): Left Atrial Appendage Closure (LAAC)
B: Arm Label: Cilostazol+ Probucol; Type: EXPERIMENTAL; Interventions: Drug: Cilostazol, Drug: Probucol, Drug: placebo of aspirin, Device: ankle-brachial index (ABI), Device: intima-medial thickness (IMT), Device: new asymptomatic brain hemorrhage, Device: new ischemic lesions on follow-up FLAIR images | Arm Label: Aspirin + Probucol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Probucol, Drug: Aspirin, Drug: placebo of cilostazol, Device: ankle-brachial index (ABI), Device: intima-medial thickness (IMT), Device: new asymptomatic brain hemorrhage, Device: new ischemic lesions on follow-up FLAIR images | Arm Label: Cilostazol; Type: EXPERIMENTAL; Interventions: Drug: Cilostazol, Drug: placebo of aspirin, Device: ankle-brachial index (ABI), Device: intima-medial thickness (IMT), Device: new asymptomatic brain hemorrhage, Device: new ischemic lesions on follow-up FLAIR images | Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: placebo of cilostazol, Device: ankle-brachial index (ABI), Device: intima-medial thickness (IMT), Device: new asymptomatic brain hemorrhage, Device: new ischemic lesions on follow-up FLAIR images | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): Cilostazol, Cilostazol+ Probucol | Intervention Type: DRUG; Name: Probucol; Assigned to Arm(s): Aspirin + Probucol, Cilostazol+ Probucol | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin, Aspirin + Probucol | Intervention Type: DRUG; Name: placebo of cilostazol; Assigned to Arm(s): Aspirin, Aspirin + Probucol | Intervention Type: DRUG; Name: placebo of aspirin; Assigned to Arm(s): Cilostazol, Cilostazol+ Probucol | Intervention Type: DEVICE; Name: ankle-brachial index (ABI); Assigned to Arm(s): Aspirin, Aspirin + Probucol, Cilostazol, Cilostazol+ Probucol | Intervention Type: DEVICE; Name: intima-medial thickness (IMT); Assigned to Arm(s): Aspirin, Aspirin + Probucol, Cilostazol, Cilostazol+ Probucol | Intervention Type: DEVICE; Name: new asymptomatic brain hemorrhage; Assigned to Arm(s): Aspirin, Aspirin + Probucol, Cilostazol, Cilostazol+ Probucol | Intervention Type: DEVICE; Name: new ischemic lesions on follow-up FLAIR images; Assigned to Arm(s): Aspirin, Aspirin + Probucol, Cilostazol, Cilostazol+ Probucol
C: Arm Label: LAAO group; Type: EXPERIMENTAL; Interventions: Device: Left atrial appendage closure | Arm Label: NOAC group; Type: EXPERIMENTAL; Interventions: Drug: NOAC | Intervention Type: DRUG; Name: NOAC; Assigned to Arm(s): NOAC group | Intervention Type: DEVICE; Name: Left atrial appendage closure; Assigned to Arm(s): LAAO group
D: Arm Label: Telemetric Bluetooth-enabled home BP monitors; Type: EXPERIMENTAL; Interventions: Device: A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci | Arm Label: Standard clinical care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci; Assigned to Arm(s): Telemetric Bluetooth-enabled home BP monitors

Answer: B